Redeye initiates coverage of Lytix Biopharma
2023-08-10 09:03:00
Redeye initiates coverage of Lytix Biopharma, an immuno-oncology company with a Nobel Prize Laureate on its advisory board and first-in-class oncolytic molecules in its pipeline.
Read more and download the Research Report.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/